What is new in CAR T-cell therapy for pediatric acute lymphoblastic leukemia?

During the European Society of Hematology (ESH) 2nd How I manage: CAR T therapies and bispecific antibodies for my...

Is CAR T-cell therapy a safe and effective treatment option for R/R T-ALL and lymphoma?

During the 2023 Society of Hematologic Oncology (SOHO) Congress, the ALL Hub spoke to Maksim Mamonkim, Baylor...

When and how should MRD be measured in Philadelphia-negative ALL?

During the 2023 Society of Hematologic Oncology (SOHO) Congress, the ALL Hub spoke to Elias Jabbour, MD Anderson Cancer Center,...

What are the challenges of sequencing immunotherapies in adults with ALL?

During the 2023 Society of Hematologic Oncology Congress (SOHO), the ALL Hub spoke to Bijal Shah, Moffitt Cancer Center,...

ESMO clinical practice guidelines: Targeted therapies for adult acute lymphoblastic leukemia

Here, we summarize the ESMO clinical practice guidelines published by Hoelzer et al., highlighting the...

Progress and challenges of CAR T-cell therapies for T-cell leukemia and lymphoma

Here, we summarize a review by Angelos et al. on the progress and challenges of CAR T-cell therapies and...

Nelarabine for the treatment of T-cell acute lymphoblastic leukemia/lymphoma

Here, we summarize a review of nelarabine published by Miller et al.1 that highlights the challenges, opportunities, and...

Is CAR T-cell therapy a safe and effective treatment option for R/R T-ALL and lymphoma?

During the 2023 Society of Hematologic Oncology (SOHO) Congress, the ALL Hub spoke to Maksim Mamonkim, Baylor...

ESMO clinical practice guidelines: Targeted therapies for adult acute lymphoblastic leukemia

Here, we summarize the ESMO clinical practice guidelines published by Hoelzer et al., highlighting the...

Efficacy and safety of CD22/CD19 dual-targeted CAR T-cell therapy in B-cell malignancies

Here, we summarize the article by Nguyen et al, on the safety and efficacy of CD22/CD19 dual targeted CAR...

Real-world efficacy of CAR T cells for posttransplant relapse in patients with B-ALL

In this article, we summarize the results of the first real-world study of tisa-cel in patients with B-ALL.

Efficacy and safety of obe-cel in R/R adult B-ALL: Phase II FELIX study

Here, we summarize the efficacy and safety results of the phase II FELIX study investigating obe-cel in adult patients with R/R...

ESMO clinical practice guidelines: Targeted therapies for adult acute lymphoblastic leukemia

Here, we summarize the ESMO clinical practice guidelines published by Hoelzer et al., highlighting the...

Nelarabine for the treatment of T-cell acute lymphoblastic leukemia/lymphoma

Here, we summarize a review of nelarabine published by Miller et al.1 that highlights the challenges, opportunities, and...

Is CAR T-cell therapy a safe and effective treatment option for R/R T-ALL and lymphoma?

During the 2023 Society of Hematologic Oncology (SOHO) Congress, the ALL Hub spoke to Maksim Mamonkim, Baylor...

Progress of targeted therapies and immunotherapies in T-ALL/LBL

Here, we summarize a review by Huang et al. on the progress of targeted therapies and immunotherapies in the treatment of patients with...